SSII SS Innovations International, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1676163 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY27.3%
TTM net income YoY15.5%
TTM EPS YoY-16.7%
Revenue 3-yr CAGR104.7%
Net income 3-yr CAGR—
Margins
Gross margin47.7%
Operating margin-27.7%
Net margin-31.5%
FCF margin—
EBITDA margin-24.8%
Returns
ROE-32.3%
ROA-17.4%
ROIC (approx.)-28.4%
Asset turnover0.55x
Leverage & solvency
Liabilities / assets48.3%
Debt / equity0.03x
Current ratio2.10x
Interest coverage-8.95x
Cash quality & payout
Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $42.48M | $20.65M | $5.88M | $1.44M | — |
| Cost of revenue | $22.94M | $12.20M | $5.15M | $1.38M | — |
| Gross profit | $19.54M | $8.45M | $725,528 | $60,577 | — |
| R&D expense | $3.69M | $2.49M | $1.06M | $987,443 | $1,000 |
| SG&A expense | $14.85M | $10.16M | $10.06M | $1.94M | $458,801 |
| Operating income | -$8.19M | -$18.98M | -$20.27M | -$2.96M | — |
| Interest expense | $1.11M | $973,235 | $894,621 | $265,522 | — |
| Pretax income | -$8.16M | -$19.15M | -$20.88M | -$3.21M | -$1.48M |
| Income tax | $3.97M | — | — | — | — |
| Net income | -$12.13M | -$19.15M | -$20.88M | -$3.21M | -$1.48M |
| EBITDA | -$7.12M | -$18.54M | -$20.12M | -$2.86M | — |
| EPS (basic) | -0.06 | -0.11 | -0.14 | -0.03 | -0.05 |
| EPS (diluted) | -0.06 | -0.11 | -0.14 | -0.03 | -0.05 |
| Weighted avg. shares (diluted) | 198.70M | 181.20M | 152.07M | 128.16M | 28.48M |
| Banking | |||||
| Net interest income | $497,549 | $335,222 | $151,497 | $2,994 | — |
| Deposits | — | — | $4.96M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $3.21M | $6.62M | $7.09M | $274,625 | $87,709 |
| Receivables | $12.40M | $4.47M | $1.90M | $156,857 | — |
| Inventory | $17.06M | $10.21M | $7.02M | $904,103 | — |
| Current assets | $48.77M | $27.42M | $21.43M | $4.10M | $408,065 |
| PP&E, net | $9.10M | $5.39M | $706,405 | $417,014 | $20,542 |
| Total assets | $74.23M | $42.39M | $31.52M | $6.98M | $428,607 |
| Current liabilities | $26.24M | $21.33M | $8.47M | $7.77M | $287,281 |
| Short-term debt | $11.44M | — | $510,189 | $120,880 | — |
| Long-term debt | — | — | $510,189 | $469,017 | — |
| Total debt | — | — | $1.02M | $589,897 | — |
| Total liabilities | $36.01M | $28.93M | $11.80M | $9.66M | -$157,004 |
| Shareholders' equity | $38.22M | $13.46M | $19.72M | -$2.68M | $585,611 |
| Net debt | — | — | -$6.07M | $315,272 | — |
| Shares outstanding | 194.17M | 171.58M | 170.71M | 128.16M | 37.85M |
| Cash flow statement | |||||
| Operating cash flow | -$18.54M | -$9.50M | -$15.36M | -$5.99M | -$363,034 |
| Capital expenditure | $3.66M | $661,479 | $453,327 | $220,324 | — |
| Free cash flow | -$22.20M | -$10.16M | -$15.81M | -$6.21M | — |
| Investing cash flow | -$3.66M | -$661,479 | -$453,327 | $240,818 | $38,150 |
| Financing cash flow | $26.17M | $9.43M | $22.80M | $5.90M | $569,949 |
| Depreciation & amortization | $1.08M | $436,005 | $152,738 | $96,577 | $18,787 |
| Stock-based compensation | $8.13M | $14.34M | $9.72M | $865,468 | $767,237 |
| Share buybacks | — | — | — | — | $26,000 |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.